{"classes":[{"categories":[{"measurements":[{"comment":"1 data point, not amenable to standard deviation calculation","groupId":"OG000","spread":"NA","value":"0.45"},{"comment":"1 data point, not amenable to standard deviation calculation","groupId":"OG001","spread":"NA","value":"1.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"MY-RADS RAC 1: Highly likely to be responding"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.45","value":"1.29"},{"comment":"1 data point, not amenable to standard deviation calculation","groupId":"OG001","spread":"NA","value":"0.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"MY-RADS RAC 2: Likely to be responding"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.45","value":"1.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"MY-RADS RAC 3: Stable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Secondary Objective 1: To assess whether the novel Magnetic Resonance (MR) protocol can improve detection of longitudinal changes in tumour burden in patients with new or relapsed myeloma during therapy, compared to the International Myeloma Working Group (IMWG) Response Group classification alone.\n\nThis section compared two indicators of therapy response:\n\n1. % change in Apparent Diffusion Coefficient (ADC) measurements in participants where there was a lytic bone lesion identified on both baseline and follow-up novel MR scan amenable to ADC measurement \\[1\\].\n2. MY-RADS RAC (Myeloma Response Assessment and Diagnosis System Response Assessment Classification) based on expert radiologist interpretation of paired novel MR imaging, guided by Messiou et. al. criteria \\[1\\].\n\nRef:\n\n\\[1\\] Messiou, Christina, et al. \"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS).\" Radiology 291.1 (2019): 5-13","dispersionType":"Standard Deviation","groups":[{"description":"Patients from Group 1a who had MY-RADS RAC score","id":"OG000","title":"Group 1a: New Myeloma"},{"description":"Patients from Group 1b who had MY-RADS RAC score","id":"OG001","title":"Group 1b: Relapsed Myeloma"}],"paramType":"MEAN","populationDescription":"Participants with new or relapsed myeloma who had successfully measured paired novel MR scans at baseline and 6-month follow-up, with a successfully graded MY-RADS RAC, and a lytic bone lesion also a lytic bone lesion amenable to longitudinal calculation of % change in ADC.","reportingStatus":"POSTED","timeFrame":"Comparison between baseline and follow-up at 6 month","title":"Secondary Outcome 1: Detect Longitudinal Changes in Tumour Load With Therapy [MY-RADS RAC (Myeloma Response Assessment and Diagnosis System Response Assessment Classification) vs % Change in ADC (Apparent Diffusion Coefficient)]","type":"SECONDARY","unitOfMeasure":"ADC Ratio (follow-up / baseline)"}